



LIBRARIES
UNIVERSITY OF WISCONSIN - MADISON

Polycillin-N advertisement.

[s.l.]: [s.n.], 1960


<https://digital.library.wisc.edu/1711.dl/GT2UDQLXIWMQ58N>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

**the penicillin
you use like a
broad-spectrum
antibiotic**



new Polycillin-NTM for Injection (sodium ampicillin)

**For severe bacterial infections...
or before and after surgery**

For both intramuscular and intravenous use

Suitable both for intramuscular and intravenous use, Polycillin-N for Injection is especially useful in surgical patients with lowered resistance to infection, or when oral therapy is impractical; in severe respiratory, GI and GU infections; and in certain types of bacterial meningitis.

Bactericidal levels—rapidly

Polycillin-N for Injection provides a rapid peak of bactericidal broad-spectrum activity. It is less serum-bound than other penicillins and destroys sensitive bacteria more rapidly than older, essentially bacteriostatic broad-spectrum antibiotics.

Well tolerated

Polycillin-N for Injection is well tolerated, in both intramuscular and intravenous therapy. As a penicillin, it is notably less toxic than older broad-spectrum antibiotics in therapeutic dosage. As with any penicillin preparation, the possibility of an allergic response to this drug must be considered.

SUPPLIED: Polycillin-N for Injection. Dry-fill vials containing 250 mg. or 500 mg. of ampicillin as the sodium salt. For intramuscular or intravenous administration.
FOR ORAL THERAPY: Rx Polycillin (ampicillin trihydrate) capsules, 250 mg.

BRISTOL THERAPEUTIC SUMMARY. For complete information consult Official Package Circular. **EFFECTIVENESS:** Clinical experience has shown Polycillin-N for Injection to be effective in the treatment of infections due to susceptible strains of Gram-negative bacteria (including *Shigella*, *S. typhosa* and other *Salmonellae*, *E. coli*, *H. influenzae*, and *P. mirabilis*) as well as susceptible Gram-positive organisms such as streptococci, pneumococci, nonpenicillinase-producing staphylococci and most strains of enterococci. Polycillin-N for Injection is particularly indicated in urinary, respiratory and gastrointestinal tract infections. **SIDE EFFECTS:** Infrequently, skin rash, pruritus, urticaria and anaphylactic reactions. Mild SGOT elevations have occurred when I.M. injections have been larger and more frequent than usual and are attributed to a release of GOT at the site of injection. Increased amounts of this enzyme do not necessarily indicate liver involvement. **PRECAUTIONS:** Typical penicillin reactions may occur. Superinfections with mycotic organisms or other pathogens may also occur. Caution should be exercised in administering Polycillin-N for Injection to premature and newborn infants since experience with the drug in such patients is limited. Safety for use in pregnancy has not been established. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral form. **CONTRAINDICATIONS:** A history of serious allergic reaction to penicillin contraindicates the use of this agent. It is also contraindicated in infections caused by penicillinase-producing staphylococci or other penicillinase-producing agents. **USUAL DOSE:** Infections due to Gram-positive organisms and respiratory infections due to streptococci, pneumococci, nonpenicillinase-producing staphylococci and *H. influenzae*. Adults: 250-500 mg. q. 6 h. Infections of the genitourinary or gastrointestinal tract caused by sensitive Gram-positive or Gram-negative bacteria. Adults: 500 mg. q. 6 h.



BRISTOL

BRISTOL LABORATORIES
Division of Bristol-Myers Co.
Syracuse, New York